An Uncontrolled Open Trial of a Brief Behavioural Activation Treatment for Depression in Patients with Chronic Spontaneous Urticaria

被引:4
|
作者
Tull, Matthew T. [1 ]
Rosenblatt, Claire B. [2 ]
Berghoff, Christopher R. [3 ]
Dixon, Laura J. [4 ]
Ciarloni, Evan [2 ]
Montgomery, Denise D. [2 ]
Wheeless, Linnie E. [5 ]
Marshall, Gailen D. [2 ]
机构
[1] Univ Toledo, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA
[3] Univ South Dakota, Vermillion, SD 57069 USA
[4] Univ Mississippi, Oxford, MS USA
[5] Jackson State Univ, Jackson, MS USA
关键词
allergy; behavioural therapy; dermatology; intervention; treatment outcome; QUALITY-OF-LIFE; MEDICATION; DISORDERS; MORBIDITY; ANXIETY;
D O I
10.1017/bec.2019.5
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Chronic spontaneous urticaria (CSU) has been associated with depression and can have an impact on quality of life. Therefore, researchers have suggested the potential utility of psychological interventions for targeting depression among CSU patients. Psychological interventions that may hold the most promise are those that are brief and easily transportable, such as brief behavioural activation treatment for depression. We report results of a preliminary investigation of an uncontrolled open trial of a one-session behavioural activation treatment for depression designed for patients with CSU (BATD-CSU) at a university-based allergy and immunology clinic. Participants were 11 females with chronic, poorly controlled urticaria and symptoms of depression. Following the completion of pretreatment questionnaires, participants were administered BATD-CSU primarily by non-mental health professionals trained and supervised in its delivery. One month post-BATD-CSU, participants completed follow-up questionnaires. Participants exhibited significant reductions in depression severity, avoidance/rumination, and work/school impairment. BATD-CSU was also associated with improvements in urticaria control one month post-treatment. Moreover, five of nine patients reported reliable and clinically significant improvement on at least one outcome. Results demonstrate that BATD-CSU may have benefits for CSU patients even when consisting of one session and delivered by professionals with limited background in psychological interventions, thus speaking to its feasibility and transportability.
引用
收藏
页码:75 / 83
页数:9
相关论文
共 50 条
  • [41] ESTIMATING THE TREATMENT COSTS FOR PATIENTS WITH CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA IN TAIWAN
    Tang, C.
    Chu, C.
    Cho, Y.
    Jiang, J.
    Lin, E., I
    VALUE IN HEALTH, 2015, 18 (03) : A181 - A181
  • [42] Effect of omalizumab treatment on peripheral nerves in patients with chronic spontaneous urticaria
    Altunisik, Erman
    Inan Dogan, Esra
    CUTANEOUS AND OCULAR TOXICOLOGY, 2021, 40 (02) : 130 - 134
  • [43] Chronic Spontaneous Urticaria patients under Treatment with Omalizumab: Our Experience
    Cervera Garcia, Maria
    Perez-Alzate, Diana
    Torres Rojas, Isabel
    Blanca Lopez, Natalia
    Prieto-Moreno, Ana
    Lopez-Gonzalez, Paula
    Haroun, Elisa
    Vazquez de la Torre, Maria
    Somoza Alvarez, Maria Luisa
    Blanco, Carlos
    Luisa Quinones, Maria
    Javier Ruano, Francisco
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB178 - AB178
  • [44] Assessing Preferences of Patients with Chronic Spontaneous Urticaria for Injectable Treatment Profiles
    Gimenez-Arnau, Ana Maria
    Balp, Maria-Magdalena
    Danyliv, Andrii
    Winders, Tonya
    O'Donoghue, James
    Kleebach, Joern
    Morrison, Samantha
    Walsh, Shaun
    Mueller, Maike
    Lopez-Ortiz, Daniela
    Maurer, Marcus
    Bernstein, Jonathan A.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2025, 18 (02): : 173 - 185
  • [45] Initial Open Trial of a Computerized Behavioral Activation Treatment for Depression
    Spates, C. Richard
    Kalata, Alyssa H.
    Ozeki, Satoshi
    Stanton, Cory E.
    Peters, Sofia
    BEHAVIOR MODIFICATION, 2013, 37 (03) : 259 - 297
  • [46] Behavioral Activation for the Treatment of Atypical Depression: A Pilot Open Trial
    Weinstock, Lauren M.
    Munroe, Mary K.
    Miller, Ivan W.
    BEHAVIOR MODIFICATION, 2011, 35 (04) : 403 - 424
  • [47] Basophil activation test in chronic spontaneous urticaria (CSU)
    Taka, S.
    Aggelidis, X.
    Giogli, V
    Pasali, M.
    Dakoula, M.
    Papadopoulos, N. G.
    Makris, M.
    ALLERGY, 2019, 74 : 176 - 176
  • [48] EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial
    Zhang, Ditte Georgina
    Sorensen, Jennifer Astrup
    Ghazanfar, Misbah Noshela
    Ali, Zarqa
    Vestergaard, Christian
    Thyssen, Jacob
    Egeberg, Alexander
    Thomsen, Simon Francis
    BMJ OPEN, 2025, 15 (01):
  • [49] Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations
    Kaplan, Allen P.
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2017, 9 (06) : 477 - 482
  • [50] Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
    Maurer, Marcus
    Rosen, Karin
    Hsieh, Hsin-Ju
    Saini, Sarbjit
    Grattan, Clive
    Gimenez-Arnau, Ana
    Agarwal, Sunil
    Doyle, Ramona
    Canvin, Janice
    Kaplan, Allen
    Casale, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (10): : 924 - 935